HADIYA HUSSAINI: Open Payments
NPI 1184359762 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,844 in 59 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,844
Food & beverage: $1,771Education: $74
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 14 | $436 |
| AstraZeneca Pharmaceuticals LP | 9 | $281 |
| Novartis Pharmaceuticals Corporation | 10 | $185 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $124 |
| GENZYME CORPORATION | 1 | $122 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| Genentech USA, Inc. | 1 | $120 |
| Lilly USA, LLC | 1 | $110 |
| Incyte Corporation | 4 | $106 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $72 |
Products named: DUPIXENT, XOLAIR, CUVITRU, NUCALA, EBGLYSS, Opzelura, FASENRA, Rhapsido.
Industry payments across TX — which companies pay providers there.
